PT  - JOURNAL ARTICLE
AU  - MacMullan, Melanie A.
AU  - Chellamuthu, Prithvi
AU  - Mades, Aubree
AU  - Das, Sudipta
AU  - Turner, Fred
AU  - Slepnev, Vladimir I
AU  - Ibrayeva, Albina
TI  - Rapid detection of SARS-CoV-2 antibodies in oral fluids
AID  - 10.1101/2020.10.12.20210609
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.12.20210609
4099  - http://medrxiv.org/content/early/2020/10/14/2020.10.12.20210609.short
4100  - http://medrxiv.org/content/early/2020/10/14/2020.10.12.20210609.full
AB  - Current commercially available methods for reliably detecting antibodies against SARS-CoV-2 remain expensive and inaccessible due to the need for whole blood collection by highly trained phlebotomists using personal protective equipment (PPE). We evaluated an antibody detection approach utilizing the OraSure® Technologies’ Oral Antibody Collection Device (OACD) and their proprietary SARS-CoV-2 total antibody detection enzyme-linked immunosorbent assay (ELISA). We found that the OraSure® test for total antibody detection in oral fluid had comparable sensitivity and specificity to serum-based ELISAs while presenting a more affordable and accessible system with the potential for self-collection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical specimens were collected under the UCLA Institutional Review Board (IRB) approved study protocol IRB#20-000703. The UCLA IRB determined the protocol was of minimal risk and that verbal informed consent was sufficient for the research under 45 CFR 46.117(c). The study team complied with all UCLA policies and procedures, as well as with all applicable Federal, State, and local laws regarding the protection of human subjects in research as stated in the approved IRB. For this study, we obratined three specimens: oral fluid for viral PCR testing, blood via venipuncture, and one oral fluid specimens for antibody testing.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFull dataset is available upon request